Oncology

Oncology·MeSH: Neoplasms

60 drugs in development·42 companies·11 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
fludeoxyglucose f18	BRIGHT MINDS BIOSCIENCES INC. (DRUG)
fludeoxyglucose f18	Cardinal Health Inc. (CAH)

Phase 2(5)

Drug	Company
Evalstotug (BA3071)	BioAtla, Inc. (BCAB)
Mivavotinib (CB-659)	Calithera Biosciences, Inc. (CALA)
PYX-107	Pyxis Oncology, Inc. (PYXS)
Sapanisertib (CB-228)	Calithera Biosciences, Inc. (CALA)
zelenectide pevedotin (formerly BT8009)	BICYCLE THERAPEUTICS PLC (BCYC)

Phase 1(12)

Drug	Company
bermekimab	XBiotech Inc. (XBIT)
BT1718	BICYCLE THERAPEUTICS PLC (BCYC)
BT7401	BICYCLE THERAPEUTICS PLC (BCYC)
CB-708 (ATG-037)	Calithera Biosciences, Inc. (CALA)
entolimod	Statera Biopharma, Inc. (CBLI)
EphA2 (BRC)	BICYCLE THERAPEUTICS PLC (BCYC)
INCB001158	Calithera Biosciences, Inc. (CALA)
rbm39 degrader	BeyondSpring Inc. (BYSI)
sapu-003	Oncotelic Therapeutics, Inc. (OTLC)
sl-9258	Shattuck Labs, Inc. (STTK)
trk-950	Apexigen, Inc. (APGN)
true human antibodies targeting il-1a	XBiotech Inc. (XBIT)

Preclinical(33)

Drug	Company
a2b antagonists	REBUS HOLDINGS, INC. (NSPX)
Aarvik ADC program	ArriVent BioPharma, Inc. (AVBP)
ABS-301	Absci Corporation (ABSI)
aeol 10150	AEOLUS PHARMACEUTICALS, INC. (AOLS)
Allogeneic CAR T cell therapy	Intellia Therapeutics, Inc. (NTLA)
ALTA-002	ALX ONCOLOGY HOLDINGS INC (ALXO)
arx102	Ambrx Biopharma Cayman, Inc. (AMAM)
bt1702	BICYCLE THERAPEUTICS PLC (BCYC)
BT7455	BICYCLE THERAPEUTICS PLC (BCYC)
CA-327	CURIS INC (CRIS)
ca21	IMMUNE DESIGN CORP. (IMDZ)
CB-668	Calithera Biosciences, Inc. (CALA)
Degrader Antibody Conjugates (DACs) programs	Nurix Therapeutics, Inc. (NRIX)
determacni	Insight Molecular Diagnostics Inc. (IMDX)
determaio	Insight Molecular Diagnostics Inc. (IMDX)
dual a2a/a2b antagonists	REBUS HOLDINGS, INC. (NSPX)
ex vivo t-cell therapeutic products	Prime Medicine, Inc. (PRME)
fsi-189	Forty Seven, Inc. (FTSV)
global liquid biopsy companion diagnostic	MYRIAD GENETICS INC (MYGN)
linebacker	IMPACT BIOMEDICAL INC. (IBO)
linebacker-1	IMPACT BIOMEDICAL INC. (IBO)
linebacker-2	IMPACT BIOMEDICAL INC. (IBO)
lnc-002	REBUS HOLDINGS, INC. (NSPX)
lnc-003	REBUS HOLDINGS, INC. (NSPX)
lockbody platform products	Centessa Pharmaceuticals plc (CNTA)
MIE-101	Mosaic ImmunoEngineering Inc. (CPMV)
mm-401	MERRIMACK PHARMACEUTICALS INC (MACK)
MT1-MMP	BICYCLE THERAPEUTICS PLC (BCYC)
next generation ex vivo t-cell therapies	Prime Medicine, Inc. (PRME)
Novel HPK1 degraders (discovery collaboration)	Cullinan Therapeutics, Inc. (CGEM)
patrol platform	NeuBase Therapeutics, Inc. (NBSE)
sy-12882	Syros Pharmaceuticals, Inc. (SYRS)
xp-102	XYNOMIC PHARMACEUTICALS HOLDINGS, INC. (BCACU)

Unknown(5)

Drug	Company
Asuragen-branded products	BIO-TECHNE Corp (TECH)
Next generation bispecific antibody platform	Celldex Therapeutics, Inc. (CLDX)
Quiescin Sulfhydryl Oxidase 1 (QSOX1) license	AXIM BIOTECHNOLOGIES, INC. (AXIM)
versamune	PDS Biotechnology Corp (PDSB)
Vysis® FISH product line	ABBOTT LABORATORIES (ABT)

Phase 1/Phase 2(3)

Drug	Company
ABCL386	AbCellera Biologics Inc. (ABCL)
arq 761	ARQULE INC (ARQL)
telomir-1	Telomir Pharmaceuticals, Inc. (TELO)

Compare drugs

fludeoxyglucose f18 vs Evalstotug (BA3071)fludeoxyglucose f18 vs Mivavotinib (CB-659)fludeoxyglucose f18 vs PYX-107

Frequently asked questions

How many drugs are in development for Oncology?

BioSniper tracks 60 drugs in development for Oncology across 42 companies.

How many clinical trials target Oncology?

There are 11 clinical trials targeting Oncology tracked by BioSniper.

Deep-dive into Oncology

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis